As proof of concept, targeting VLA-4 (α4) disrupts the VCAM1–VLA-4 interactions between CTC and immunosuppressive DPT and inhibits metastasis, ultimately improving breast cancer outcomes. The gene discussed is VCAM1; the disease is breast cancer.